Kamaleldin E. Elagib

919 total citations
19 papers, 697 citations indexed

About

Kamaleldin E. Elagib is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Kamaleldin E. Elagib has authored 19 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 9 papers in Molecular Biology and 7 papers in Genetics. Recurrent topics in Kamaleldin E. Elagib's work include Acute Myeloid Leukemia Research (10 papers), Platelet Disorders and Treatments (8 papers) and Hemoglobinopathies and Related Disorders (5 papers). Kamaleldin E. Elagib is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Platelet Disorders and Treatments (8 papers) and Hemoglobinopathies and Related Disorders (5 papers). Kamaleldin E. Elagib collaborates with scholars based in United States, France and Canada. Kamaleldin E. Elagib's co-authors include Adam N. Goldfarb, Lorrie L. Delehanty, Frederick Racke, Jing-Ruey Joanna Yeh, David A. Sweetser, Randall T. Peterson, Kathleen M. Munson, Young‐Jin Choi, Ivailo S. Mihaylov and Michael J. Birrer and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Kamaleldin E. Elagib

19 papers receiving 693 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kamaleldin E. Elagib United States 12 420 358 154 128 105 19 697
Marloes R. Tijssen United Kingdom 16 431 1.0× 430 1.2× 100 0.6× 166 1.3× 143 1.4× 29 852
Kristen D. McKnight Canada 9 372 0.9× 269 0.8× 125 0.8× 74 0.6× 158 1.5× 10 670
JE Visvader Australia 6 537 1.3× 212 0.6× 244 1.6× 74 0.6× 117 1.1× 13 723
Boris Guyot France 13 552 1.3× 259 0.7× 91 0.6× 175 1.4× 120 1.1× 27 821
Patricia Sousa United States 10 507 1.2× 163 0.5× 225 1.5× 69 0.5× 138 1.3× 22 721
Stephen J. Loughran Australia 10 315 0.8× 268 0.7× 61 0.4× 110 0.9× 95 0.9× 14 536
Lorrie L. Delehanty United States 11 286 0.7× 387 1.1× 46 0.3× 211 1.6× 76 0.7× 16 649
Zhongling Cai United States 6 623 1.5× 666 1.9× 181 1.2× 144 1.1× 126 1.2× 9 966
Melania Barile United Kingdom 8 335 0.8× 348 1.0× 73 0.5× 71 0.6× 308 2.9× 13 656
Xiongwei Cai China 14 466 1.1× 258 0.7× 198 1.3× 64 0.5× 231 2.2× 30 785

Countries citing papers authored by Kamaleldin E. Elagib

Since Specialization
Citations

This map shows the geographic impact of Kamaleldin E. Elagib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamaleldin E. Elagib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamaleldin E. Elagib more than expected).

Fields of papers citing papers by Kamaleldin E. Elagib

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kamaleldin E. Elagib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamaleldin E. Elagib. The network helps show where Kamaleldin E. Elagib may publish in the future.

Co-authorship network of co-authors of Kamaleldin E. Elagib

This figure shows the co-authorship network connecting the top 25 collaborators of Kamaleldin E. Elagib. A scholar is included among the top collaborators of Kamaleldin E. Elagib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kamaleldin E. Elagib. Kamaleldin E. Elagib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Goldfarb, Adam N., Ranjit Kumar Sahu, Kamaleldin E. Elagib, et al.. (2021). Iron control of erythroid microtubule cytoskeleton as a potential target in treatment of iron-restricted anemia. Nature Communications. 12(1). 1645–1645. 10 indexed citations
2.
Balogh, Péter, Emmalee R. Adelman, John V. Pluvinage, et al.. (2019). RUNX3 levels in human hematopoietic progenitors are regulated by aging and dictate erythroid-myeloid balance. Haematologica. 105(4). 905–913. 12 indexed citations
3.
Elagib, Kamaleldin E., et al.. (2018). Megakaryocyte ontogeny: Clinical and molecular significance. Experimental Hematology. 61. 1–9. 13 indexed citations
4.
Elagib, Kamaleldin E., Goar Mosoyan, Shadi Khalil, et al.. (2017). Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition. Journal of Clinical Investigation. 127(6). 2365–2377. 38 indexed citations
5.
Elagib, Kamaleldin E., Goar Mosoyan, Ewelina Zasadzińska, et al.. (2016). An IGF2BP3-Cdk9 Pathway Governs the Human Fetal-Adult Megakaryocyte Transition. Blood. 128(22). 886–886. 1 indexed citations
6.
7.
Elagib, Kamaleldin E., Jeremy D. Rubinstein, Lorrie L. Delehanty, et al.. (2013). Calpain 2 Activation of P-TEFb Drives Megakaryocyte Morphogenesis and Is Disrupted by Leukemogenic GATA1 Mutation. Developmental Cell. 27(6). 607–620. 24 indexed citations
8.
Rubinstein, Jeremy D., Kamaleldin E. Elagib, & Adam N. Goldfarb. (2012). Cyclic AMP Signaling Inhibits Megakaryocytic Differentiation by Targeting Transcription Factor 3 (E2A) Cyclin-dependent Kinase Inhibitor 1A (CDKN1A) Transcriptional Axis. Journal of Biological Chemistry. 287(23). 19207–19215. 8 indexed citations
9.
Rubinstein, Jeremy D., Kamaleldin E. Elagib, & Adam N. Goldfarb. (2011). Cyclic AMP Signaling Inhibits Megakaryopoiesis by Targeting An E2A-CDKN1A Transcriptional Axis. Blood. 118(21). 915–915. 1 indexed citations
10.
Yeh, Jing-Ruey Joanna, Kathleen M. Munson, Kamaleldin E. Elagib, et al.. (2009). Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nature Chemical Biology. 5(4). 236–243. 127 indexed citations
11.
12.
Elagib, Kamaleldin E., Ivailo S. Mihaylov, Lorrie L. Delehanty, et al.. (2008). Cross-talk of GATA-1 and P-TEFb in megakaryocyte differentiation. Blood. 112(13). 4884–4894. 37 indexed citations
13.
Elagib, Kamaleldin E., Lorrie L. Delehanty, & Adam N. Goldfarb. (2008). A Murine Model for the Transient Myeloproliferative Disorder of Down Syndrome: Phenotypic Influence of p53 on Reversible Megakaryoblastic Disorder. Blood. 112(11). 688–688. 6 indexed citations
14.
Elagib, Kamaleldin E. & Adam N. Goldfarb. (2007). Regulation of RUNX1 Transcriptional Function by GATA-1. Critical Reviews in Eukaryotic Gene Expression. 17(4). 271–280. 13 indexed citations
15.
Elagib, Kamaleldin E. & Adam N. Goldfarb. (2006). Oncogenic pathways of AML1-ETO in acute myeloid leukemia: Multifaceted manipulation of marrow maturation. Cancer Letters. 251(2). 179–186. 40 indexed citations
16.
Choi, Young‐Jin, Kamaleldin E. Elagib, Lorrie L. Delehanty, & Adam N. Goldfarb. (2006). Erythroid Inhibition by the Leukemic Fusion AML1-ETO Is Associated with Impaired Acetylation of the Major Erythroid Transcription Factor GATA-1. Cancer Research. 66(6). 2990–2996. 44 indexed citations
17.
Choi, Young‐Jin, Kamaleldin E. Elagib, & Adam N. Goldfarb. (2005). AML1-ETOMediated Erythroid Inhibition: New Paradigms for Differentiation Blockade by a Leukemic Fusion Protein. Critical Reviews in Eukaryotic Gene Expression. 15(3). 207–216. 12 indexed citations
18.
Elagib, Kamaleldin E., Mang Xiao, Isa M. Hussaini, et al.. (2004). Jun Blockade of Erythropoiesis: Role for Repression of GATA-1 by HERP2. Molecular and Cellular Biology. 24(17). 7779–7794. 55 indexed citations
19.
Elagib, Kamaleldin E., et al.. (2003). RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 101(11). 4333–4341. 254 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marloes R. Tijssen Breakdown of academic impact, for papers by Kristen D. McKnight Breakdown of academic impact, for papers by JE Visvader Breakdown of academic impact, for papers by Boris Guyot Breakdown of academic impact, for papers by Patricia Sousa Breakdown of academic impact, for papers by Stephen J. Loughran Breakdown of academic impact, for papers by Lorrie L. Delehanty Breakdown of academic impact, for papers by Zhongling Cai Breakdown of academic impact, for papers by Melania Barile Breakdown of academic impact, for papers by Xiongwei Cai
Rankless by CCL
2026